The Lynx Group

Yana G. Najjar and John M. Kirkwood


Authored Items

Melanoma: A New Frontier in Personalized Medicine

May 2016, Vol. 5, No. 4 - Melanoma

The standard of care for patients with advanced-stage melanoma has shifted from empiric treatment with chemotherapy that has low response rates to targeted therapy with response rates that are substantially higher, and immunotherapy, which has shown the most durable disease control. Chemotherapy is not intrinsically able to differentiate between tumor [ Read More ]

Sign me up!